Receptor-Mediated Drug Delivery Systems Targeting to Glioma

Glioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radi...

Full description

Bibliographic Details
Main Authors: Shanshan Wang, Ying Meng, Chengyi Li, Min Qian, Rongqin Huang
Format: Article
Language:English
Published: MDPI AG 2015-12-01
Series:Nanomaterials
Subjects:
Online Access:http://www.mdpi.com/2079-4991/6/1/3
id doaj-244ba754fb194e1ab2bb7e841c899f71
record_format Article
spelling doaj-244ba754fb194e1ab2bb7e841c899f712020-11-25T01:09:40ZengMDPI AGNanomaterials2079-49912015-12-0161310.3390/nano6010003nano6010003Receptor-Mediated Drug Delivery Systems Targeting to GliomaShanshan Wang0Ying Meng1Chengyi Li2Min Qian3Rongqin Huang4Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaGlioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radiotherapy, and chemotherapy. This provides a rationale for the development of some novel therapeutic strategies. Among them, receptor-mediated drug delivery is a specific pattern taking advantage of differential expression of receptors between tumors and normal tissues. The strategy can actively transport drugs, such as small molecular drugs, gene medicines, and therapeutic proteins to glioma while minimizing adverse reactions. This review will summarize recent progress on receptor-mediated drug delivery systems targeting to glioma, and conclude the challenges and prospects of receptor-mediated glioma-targeted therapy for future applications.http://www.mdpi.com/2079-4991/6/1/3gliomablood-brain barrier (BBB)receptor-mediatedsingle ligand-modified targeting systemsdual ligand-modified targeting systems
collection DOAJ
language English
format Article
sources DOAJ
author Shanshan Wang
Ying Meng
Chengyi Li
Min Qian
Rongqin Huang
spellingShingle Shanshan Wang
Ying Meng
Chengyi Li
Min Qian
Rongqin Huang
Receptor-Mediated Drug Delivery Systems Targeting to Glioma
Nanomaterials
glioma
blood-brain barrier (BBB)
receptor-mediated
single ligand-modified targeting systems
dual ligand-modified targeting systems
author_facet Shanshan Wang
Ying Meng
Chengyi Li
Min Qian
Rongqin Huang
author_sort Shanshan Wang
title Receptor-Mediated Drug Delivery Systems Targeting to Glioma
title_short Receptor-Mediated Drug Delivery Systems Targeting to Glioma
title_full Receptor-Mediated Drug Delivery Systems Targeting to Glioma
title_fullStr Receptor-Mediated Drug Delivery Systems Targeting to Glioma
title_full_unstemmed Receptor-Mediated Drug Delivery Systems Targeting to Glioma
title_sort receptor-mediated drug delivery systems targeting to glioma
publisher MDPI AG
series Nanomaterials
issn 2079-4991
publishDate 2015-12-01
description Glioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radiotherapy, and chemotherapy. This provides a rationale for the development of some novel therapeutic strategies. Among them, receptor-mediated drug delivery is a specific pattern taking advantage of differential expression of receptors between tumors and normal tissues. The strategy can actively transport drugs, such as small molecular drugs, gene medicines, and therapeutic proteins to glioma while minimizing adverse reactions. This review will summarize recent progress on receptor-mediated drug delivery systems targeting to glioma, and conclude the challenges and prospects of receptor-mediated glioma-targeted therapy for future applications.
topic glioma
blood-brain barrier (BBB)
receptor-mediated
single ligand-modified targeting systems
dual ligand-modified targeting systems
url http://www.mdpi.com/2079-4991/6/1/3
work_keys_str_mv AT shanshanwang receptormediateddrugdeliverysystemstargetingtoglioma
AT yingmeng receptormediateddrugdeliverysystemstargetingtoglioma
AT chengyili receptormediateddrugdeliverysystemstargetingtoglioma
AT minqian receptormediateddrugdeliverysystemstargetingtoglioma
AT rongqinhuang receptormediateddrugdeliverysystemstargetingtoglioma
_version_ 1725177336995774464